Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides ...
Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in ...